NeuroSense Therapeutics Faces Nasdaq Deficiency Notices but Retains Listing Status

Neurosense Therapeutics Ltd. ( (NRSN) ) just unveiled an update.

On April 3, 2026, NeuroSense Therapeutics disclosed that it received two Nasdaq notices on April 2 stating its shares failed to meet minimum bid price and market value of listed securities requirements between February 18 and March 31, 2026. The company’s stock and warrants remain listed and trading on the Nasdaq Capital Market, while NeuroSense has until September 29, 2026 to restore both a $1.00 bid price and a $35 million market value for at least 10 consecutive trading days and is assessing options to regain compliance with an emphasis on preserving long-term shareholder value.

The most recent analyst rating on (NRSN) stock is a Buy with a $3.00 price target. To see the full list of analyst forecasts on Neurosense Therapeutics Ltd. stock, see the NRSN Stock Forecast page.

Spark’s Take on NRSN Stock

According to Spark, TipRanks’ AI Analyst, NRSN is a Neutral.

The score is primarily constrained by weak financial performance (no revenue, widening losses, and increasing cash burn), which elevates funding and dilution risk. Technical signals are mixed with a weak longer-term trend despite neutral momentum, and valuation is limited by negative earnings and no dividend support.

To see Spark’s full report on NRSN stock, click here.

More about Neurosense Therapeutics Ltd.

NeuroSense Therapeutics Ltd. is a clinical-stage biotechnology company developing combination therapies for severe neurodegenerative diseases, including ALS, Alzheimer’s and Parkinson’s disease. The company focuses on targeting multiple biological pathways based on biomarker research to address significant unmet medical needs in these indications.

Average Trading Volume: 204,174

Technical Sentiment Signal: Sell

Current Market Cap: $24.65M

For an in-depth examination of NRSN stock, go to TipRanks’ Overview page.